CDA | Evidence Driven
CDA | Evidence Driven

Treanda for indolent Non-Hodgkin Lymphoma

Details

Files
Generic Name:
Bendamustine hydrochloride
Project Status:
Complete
Therapeutic Area:
Non-Hodgkin Lymphoma and Mantle Cell Lymphoma
Manufacturer:
Lundbeck Canada Inc.
Brand Name:
Treanda
Project Line:
Reimbursement Review
Project Number:
PC0010-000
Performance Metric:
N/A — Predated performance metrics
Strength:
25 mg/vial and 100 mg/vial
Tumour Type:
Lymphoma
Indications:
Non-Hodgkin lymphoma (NHL)
Funding Request:
For patients with indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma (first line and relapse/refractory)
Review Status:
Complete
Pre Noc Submission:
Yes
Sponsor:
Lundbeck Canada Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse
pERC Meeting:
Final Recommendation Issued:

Files

Provincial Funding Summary View PDF
Bendamustine (Treanda) NHL - pERC Final Recommendation Final Recommendation November 29, 2012 View PDF
Bendamustine (Treanda) for NHL - Final Clinical Guidance Report Guidance Reports November 29, 2012 View PDF
Bendamustine (Treanda) for NHL - Final Economic Guidance Report Guidance Reports November 29, 2012 View PDF
Bendamustine (Treanda) for NHL - pERC Initial Recommendation Initial Recommendation October 4, 2012 View PDF
Bendamustine (Treanda) for NHL - PAG Feedback on Initial Recommendation Feedback November 29, 2012 View PDF
Bendamustine (Treanda) for NHL - Manufacturer (Lundbeck Canada) Feedback on Initial Recommendation Feedback November 29, 2012 View PDF
Bendamustine (Treanda) for NHL - Patient Advocacy Group (LFC) Feedback on Initial Recommendation Feedback November 29, 2012 View PDF
Bendamustine (Treanda) for NHL - Patient Advocacy Group (LFC) COI Declarations Feedback November 29, 2012 View PDF
Bendamustine (Treanda) for NHL - Patient Advocacy Group (LLSC) COI Declarations Feedback November 29, 2012 View PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : December 14, 2012